PDF herunterladen
Am J Perinatol 2024; 41(06): 730-738
DOI: 10.1055/a-1782-5860
Original Article

Randomized Noninferiority Trial of Expectant Management versus Early Treatment of Patent Ductus Arteriosus in Preterm Infants

Solomiia Potsiurko 
1   Department of Pediatrics No. 2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
,
Dmytro Dobryanskyy 
1   Department of Pediatrics No. 2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
,
Lesya Sekretar
1   Department of Pediatrics No. 2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
,
Zoryana Salabay
2   The Neonatal Intensive Care Unit of the Lviv Regional Clinical Hospital, Lviv, Ukraine
› Institutsangaben Funding None.
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Objective The study aimed to investigate, whether expectant management is noninferior to early patent ductus arteriosus (PDA) treatment with regard to the composite of mortality and/or incidence of bronchopulmonary dysplasia (BPD) in very preterm infants.

Study design A total of 208 very preterm infants of the gestational age <32 weeks, birth weight <1,500 g, chronological age <72 hours, and PDA >1.5 mm were randomized between the treatment or expectant management groups. Both, the intention-to-treat and per-protocol analyses were performed.

Results A total of 104 (50%) patients received rectal ibuprofen (n = 52) or intravenous acetaminophen (n = 52) within first 72 hours of life. In 104 (50%) infants, expectant management was used. Eight of them (8%) received rescue treatment at the median age of 7 (range: 6–13) days. PDA closure rates by the 10th day of life were 81% (n = 84) in the treatment arm, and 58% (n = 60) in the expectant management arm (p < 0.01). The median age at the time of ductus closure was 5 (range: 5–6) days in the treatment arm and 8 (range: 6–11) days in the expectant management arm (p < 0.01). At the time of discharge, ductus was closed in 83% of treated infants and in 78% of patients who were managed expectantly (p > 0.05). No significant difference between the groups was found for the primary clinical outcomes, BPD/death, or the secondary outcomes at a postmenstrual age of 36 weeks or discharge.

Conclusion Expectant management is noninferior to early PDA treatment for reducing the incidence of death/BPD. Compared with the expectant management, early pharmacological treatment provides more frequent and faster PDA closure in preterm infants with gestational age <32 weeks, but it neither reduces morbidity nor improves survival rates.

Key Points

  • PDA persistence in very preterm infants is associated with an increased risk of BPD/death.

  • PDA treatment accelerates ductus closure, but does not improve survival or reduce severe neonatal morbidity.

  • Expectant management is not associated with a higher risk of BPD/death.

Keywords

patent ductus arteriosus - early PDA treatment - noninferior - expectant management - perinatal outcomes


Publikationsverlauf

Eingereicht: 28. Dezember 2021

Angenommen: 08. Februar 2022

Accepted Manuscript online:
25. Februar 2022

Artikel online veröffentlicht:
18. April 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Sellmer A, Bjerre JV, Schmidt MR. et al. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed 2013; 98 (06) F505-F510
    Google Scholar
  • 2 Sankar MN, Bhombal S, Benitz WE. PDA: to treat or not to treat. Congenit Heart Dis 2019; 14 (01) 46-51
    CrossrefPubMedGoogle Scholar
  • 3 Sung SI, Chang YS, Chun JY. et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr 2016; 177: 66-71.e1
    CrossrefPubMedGoogle Scholar
  • 4 Schena F, Francescato G, Cappelleri A. et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. J Pediatr 2015; 166 (06) 1488-1492
    CrossrefPubMedGoogle Scholar
  • 5 Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative effectiveness of nonsteroidal anti-inflammatory drug treatment vs no treatment for patent ductus arteriosus in preterm infants. JAMA Pediatr 2017; 171 (03) e164354
    CrossrefPubMedGoogle Scholar
  • 6 Clyman RI, Hills NK, Liebowitz M, Johng S. Relationship between duration of infant exposure to a moderate-to-large patent ductus arteriosus shunt and the risk of developing bronchopulmonary dysplasia or death before 36 weeks. Am J Perinatol 2020; 37 (02) 216-223
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 El-Khuffash A, James AT, Corcoran JD. et al. A patent ductus arteriosus severity score predicts chronic lung disease or death before discharge. J Pediatr 2015; 167 (06) 1354-1361.e2
    CrossrefPubMedGoogle Scholar
  • 8 Mirza H, Garcia J, McKinley G. et al. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol 2019; 39 (12) 1648-1655
    CrossrefPubMedGoogle Scholar
  • 9 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2018; 9: CD003481
    PubMedGoogle Scholar
  • 10 Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev 2020; 1: CD010061
    PubMedGoogle Scholar
  • 11 Mitra S, Florez ID, Tamayo ME. et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA 2018; 319 (12) 1221-1238
    CrossrefPubMedGoogle Scholar
  • 12 Huang X, Wang F, Wang K. Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 2018; 31 (16) 2216-2222
    CrossrefPubMedGoogle Scholar
  • 13 Farooqui MA, Elsayed YN, Jeyaraman MM. et al. Pre-symptomatic targeted treatment of patent ductus arteriosus in preterm newborns: A systematic review and meta-analysis. J Neonatal Perinatal Med 2019; 12 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 14 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117 (04) 1113-1121
    CrossrefPubMedGoogle Scholar
  • 15 Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?. Semin Perinatol 2012; 36 (02) 123-129
    CrossrefPubMedGoogle Scholar
  • 16 Benitz WE. Committee on Fetus and Newborn, American Academy of Pediatrics. Patent ductus arteriosus in preterm infants. Pediatrics 2016; 137 (01) x
    CrossrefPubMedGoogle Scholar
  • 17 Sallmon H, Koehne P, Hansmann G. Recent advances in the treatment of preterm newborn infants with patent ductus arteriosus. Clin Perinatol 2016; 43 (01) 113-129
    CrossrefPubMedGoogle Scholar
  • 18 Hagadorn JI, Brownell EA, Trzaski JM. et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. Pediatr Res 2016; 80 (06) 785-792
    CrossrefPubMedGoogle Scholar
  • 19 Clyman RI, Liebowitz M, Kaempf J. et al; PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-TOLERATE trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr 2019; 205: 41-48.e6
    CrossrefPubMedGoogle Scholar
  • 20 Hundscheid T, Onland W, van Overmeire B. et al. Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial). BMC Pediatr 2018; 18 (01) 262
    CrossrefPubMedGoogle Scholar
  • 21 de Boode WP, Singh Y, Gupta S. et al. Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr Res 2016; 80 (04) 465-471
    Google Scholar
  • 22 Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores. J Pediatr 2001; 138 (01) 92-100
    CrossrefPubMedGoogle Scholar
  • 23 Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163 (07) 1723-1729
    CrossrefPubMedGoogle Scholar
  • 24 Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003; 23 (06) 451-456
    CrossrefPubMedGoogle Scholar
  • 25 Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978; 92 (04) 529-534
    CrossrefPubMedGoogle Scholar
  • 26 Bell MJ. Neonatal necrotizing enterocolitis. N Engl J Med 1978; 298 (05) 281-282
    CrossrefPubMedGoogle Scholar
  • 27 de Waal K, Phad N, Stubbs M, Chen Y, Kluckow M. A randomized placebo-controlled pilot trial of early targeted nonsteroidal anti-inflammatory drugs in preterm infants with a patent ductus arteriosus. J Pediatr 2021; 228: 82-86.e2
    CrossrefPubMedGoogle Scholar
  • 28 Demir N, Peker E, Ece İ, Balahoroğlu R, Tuncer O. Efficacy and safety of rectal ibuprofen for patent ductus arteriosus closure in very low birth weight preterm infants. J Matern Fetal Neonatal Med 2017; 30 (17) 2119-2125
    CrossrefPubMedGoogle Scholar